Industry

DUBLIN–(BUSINESS WIRE)–The “Dermatologicals Market by Disease, Type and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2021-2030” report has been added to ResearchAndMarkets.com’s offering. The global dermatological market was valued at $19,974.3 million in 2020, and is projected to reach $59,309.3 million by 2030, registering a CAGR of 11.5% from 2021 to 2030. Dermatological … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Transdermal Skin Patches Market, Size, Global Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis” report has been added to ResearchAndMarkets.com’s offering. Global Transdermal Skin Patches Market is expected to reach US$ 9.6 billion in 2027 from $7.8 billion in 2021, growing at a CAGR of 3.52% Transdermal skin patches … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Autotransfusion Devices Market Forecast to 2028- COVID-19 Impact and Global Analysis – by Type; Application; End User” report has been added to ResearchAndMarkets.com’s offering. Accessories Segment to Hold Largest Share of Autotransfusion Devices Market During 2021-2028 Global autotransfusion devices market size is expected to grow from US$ 1,000.26 million in 2021 to US$ … [Read more…]

New offering from Thermo Fisher Scientific expands instrument capabilities beyond allergy diagnostics PORTAGE, Mich.–(BUSINESS WIRE)–The new Phadia 2500+ series of instruments is now available for autoimmune testing in the U.S. The family of high-capacity, intuitive lab instruments supplied by Thermo Fisher Scientific, the world leader in serving science, offers reliable and unparalleled high throughput for … [Read more…]

Highlights include the launch of Spectronaut® 16, which has undergone one of its most transformative upgrades to date, and innovations to Biognosys’ proprietary TrueTarget™ and TrueDiscovery™ platforms for drug and biomarker discovery. ZURICH–(BUSINESS WIRE)–#ClinicalResearch–Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced the company is attending the American Society for Mass … [Read more…]

NEW YORK–(BUSINESS WIRE)–Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced that Eddine Saiah, Ph.D., has joined the company as Chief Scientific Officer. Dr. Saiah is an experienced drug hunter and seasoned leader with over 25 years of experience heading drug discovery, preclinical and early development in … [Read more…]

Call Center Customer Support and Digital Tools Emerge as Key Areas in Need of Improvement TROY, Mich.–(BUSINESS WIRE)–With pandemic-driven volatility in healthcare starting to subside, health spending and utilization are projected to normalize1 during the next two years. According to the J.D. Power 2022 U.S. Commercial Member Health Plan Study,SM released today, that return to … [Read more…]

The Roblox vision for bringing people together through shared experiences, plus the Akili commitment to a new era of cognitive medicine, make the companies ideal partners to deliver a reimagined patient experience BOSTON & SANTA MONICA, Calif.–(BUSINESS WIRE)–Akili Interactive (“Akili”), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, and … [Read more…]

WALTHAM, Mass. & CAMBRIDGE, England–(BUSINESS WIRE)–Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, announced that Young T. Kwon, PhD, Alchemab’s Chief Financial and Operating Officer, has succeeded Douglas A. Treco, PhD as Chief Executive Officer and member of the Board, who resigned … [Read more…]

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended March 31, 2022. Corporate and Clinical Development Highlights Include: Fortified Balance Sheet – On March 31, 2022, Can-Fite … [Read more…]